Tiger Brokers

BUZZ-Becton falls; J.P. Morgan says Novo Nordisk's bullish commentary on Wegovy pill is overdone

Reuters
Jan 24
BUZZ-Becton falls; J.P. Morgan says <a href="https://laohu8.com/S/NVO">Novo Nordisk</a>'s bullish commentary on Wegovy pill is overdone

** Shares of drug delivery device maker Becton Dickinson BDX.N fall 2.8% to $200.85 in afternoon trading

** Novo Nordisk's NOVOb.CO bullish commentary on the ramp up of its oral Wegovy obesity drug led to fears of "cannibalization" from the traditional injectable market, J.P. Morgan analysts say

** "On the one hand, strong demand for oral GLP-1s could serve as an incremental challenge for Becton Dickinson's aspirations of leveraging its expertise in prefillable syringes in GLP-1 biologics"- J.P. Morgan

** BDX makes drug delivery devices like prefilled syringes and autoinjectors used for injectable GLP-1 drugs such as Novo's Ozempic and Wegovy

** Rapid uptake of oral drugs could reduce demand for BDX's products

** Despite this, brokerage expects injectables to play an important role in the obesity treatment paradigm, adding that orals will be mostly used for maintenance

** BDX stock dipped 14.5% in 2025

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10